-+ 0.00%
-+ 0.00%
-+ 0.00%

Heidelberg Pharma says China NMPA clears HDP-101 combo trial in multiple myeloma

PUBT·08/26/2026 16:30:30
Listen to the news
Heidelberg Pharma says China NMPA clears HDP-101 combo trial in multiple myeloma
  • China’s NMPA cleared a Phase Ib/II trial of pamlectabart tismanitin (HDP-101) in combination therapy for relapsed/refractory multiple myeloma.
  • Huadong Medicine will run the China study, testing HDP-101 with standard regimens; Huadong will fund development costs.
  • HDP-101 is already in Phase I/IIa monotherapy trials in the US and Europe, with a China bridging study underway since March 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2389280_de) on August 26, 2026, and is solely responsible for the information contained therein.